Michael Forbes, CEO of Adastra, claimed in his First press release: “Damage reduction is a critically essential and mainstream subject, and we've been being on the forefront of drug regulations throughout the board.” “We're going to evaluate how the commercialization of the compound suits in with our company design at Adastra in order to p